

Anti-CD38 Antibody (Daratumumab)

Introduction

Daratumumab (Anti-Human CD38) is a first-in-class specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effects. Daratumumab impairs the adhesion of MM cells, thereby increasing the sensitivity of MM to proteasome inhibition.

Product parameters

Alternative Names	Darzalex, Zhaoke, JNJ-54767414
Target Accession	P28907
Target	CD38
CAS number	945721-28-8
Molecular Weight	145.26 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD38 NHis at 2 ug/mL can bind Anti-CD38 Antibody (Daratumumab), EC50=0.04792 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

